METACURE *at a glance*

MetaCure is a private commercial-stage company which aims to provide a better way to manage diabetes, focusing on the impact on the day-to-day lives of patients. The company makes the novel CE-approved DIAMOND implantable device for treatment of type 2 diabetes and has offices in Hamilton (Bermuda), New York (USA), Stuttgart (Germany), and Sydney (Australia).

>400 million
Number of people with type 2 diabetes worldwide.[1]

>240 million
Estimated number of obese type 2 diabetes patients who are refractory to oral medication.[2,3,4]

>60%
Percentage of type 2 diabetes patients who are obese.[4]

>$800 billion
Yearly cost of diabetes globally.[1]

$27 billion
Yearly global expenditure on insulin.[5]

Up to 94%
Percentage of insulin users who show symptoms of anxiety and distress from insulin injections.[6]

The Need – the diabetes pandemic

Over a hundred million type 2 diabetes patients and their caring physicians look to insulin or other injectable medication once oral medication fails. These patients face a variety of challenges affecting their day to day life. Often several blood sugar tests are needed daily and some patients may require up to four injections per day. Common side effects and complications of insulin therapy include weight gain, hypertension and, in severe cases, hypoglycemia shocks requiring hospitalization. Additionally, many patients cannot tolerate GLP-1 agonist therapy due to nausea, vomiting and other gastrointestinal disturbances. These challenges ultimately lead to a lower compliance rate, further complications and increased healthcare costs.

Our Solution – an alternative to insulin

Recognizing the need for a better way to manage diabetes, MetaCure developed a one-time intervention which is as effective as insulin but avoids many of the side-effects and complications associated with it. DIAMOND is delivered through a small pacemaker-like device which is implanted under the abdomen skin and connected by small electrodes to the stomach. The device automatically detects when eating begins, and then sends gentle signals to the stomach muscles. As a result, the therapy restores the physiological synchronization between food intake and natural hormone secretion, and lowers post meal glucose levels. Additionally, DIAMOND causes earlier satiation resulting in sustained weight loss.

The DIAMOND (Tantalus) System is CE marked and available for commercial use. The DIAMOND II System is not CE marked currently.

METACURE *at a glance*

Results and company status

MetaCure has successfully completed trials with over 300 patients with up to three years of follow up, demonstrating the safety and efficacy of the DIAMOND therapy. The DIAMOND device is CE approved and the company is initiating commercial activities in Europe and other international markets.

83%
Patients who improved their glycemic control[7]

85%
Patients who experienced weight reduction[7]

3 Years
The observation period in our long-term study[8]

Efficacy[8,9,10,11]

- HbA1c reduction of 1%
- Sustained results over several years
- Durable weight loss of 5 - 10Kg
- Reduced blood pressure by 10 mmHg

Safety[8,10,12,13,14]

- Safe implantation procedure
- Does not cause hypoglycemia
- Minimal side effects

The team

Our international managerial team brings a wealth of experience in the medical device field:

Shlomo Ben-Haim, Chairman and Founder
Adrian Gilmore, Chief Executive Officer
Mateusz Zelewski, President and COO
Deborah L. Morley, VP Regulatory Affairs & Quality Assurance
Amir Cohen, Chief Financial Officer

Contact information

Mrs. Sharon Alon
Email: Media@MetaCure.com
Tel: +1 347-761-3350
Website: www.MetaCure.com

DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets. DIAMOND is not approved for use in the USA.

[1] Global Report on Diabetes. World Health Organization, 2016 [2] United States Census Bureau 2015, Accessed 18 August 2015. [3] MetaCure estimates, 2016. [4] Wong SK, Kong AP, Luk AO, et al. A pilot study to compare meal-triggered gastric electrical stimulation and insulin treatment in Chinese obese type 2 diabetes. Diabetes Technol Ther. 2015;17(4):283-90. [5] Human Insulin Market Development and Demand Forecast to 2020, P&S Market Research, 2015. [6] Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012;14(8):741-7. [7] Lebovitz H.E., Zalewski M., Gastric Electrical Stimulation (GES) in T2DM Improves Long-term Glycemic Control Through a Triglyceride-dependent Mechanism; Abstract # OP-0078. Presented at the IDF World Diabetes Congress Melbourne 2013, December 3, 2013, Melbourne. [8] Lebovitz HE, Ludvik B, Yaniv I, et al. Treatment of Patients with Obese Type 2 Diabetes with Tantalus-DIAMOND® Gastric Electrical Stimulation: Normal Triglycerides Predict Durable Effects for at Least 3 Years. Horm Metab Res. 2015;47(6):456-62. [9] Wong SK, Kong AP, Luk AO, et al. A pilot study to compare meal-triggered gastric electrical stimulation and insulin treatment in Chinese obese type 2 diabetes. Diabetes Technol Ther. 2015;17(4):283-90. [10] Lebovitz HE, Ludvik B, Kozakowski J, et al. Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-mediated stimulation. A randomized blinded cross-over trial. Physiol Rep. 2015;3(7). [11] Lebovitz HE, Ludvik B, Yaniv I, et al. Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm. Diabet Med. 2013;30(6):687-93. [12] Bohdjalian A, Prager G, Rosak C, et al. Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation. Obes Surg. 2009;19(9):1221-7. [13] Sanmiguel CP, Conklin JL, Cunneen SA, et al. Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control. J Diabetes Sci Technol. 2009;3(4):964-70. [14] Bohdjalian A, Prager G, Aviv R, et al. One-year experience with Tantalus: a new surgical approach to treat morbid obesity. Obes Surg. 2006;16(5):627-34.